The role of the microbiome in NAFLD and NASH
Open accessThe DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly becoming the most prevalent liver disease worldwide. A sizable minority of NAFLD patients develop nonalcoholic steatohepatitis (NASH), which is characterized by inflammatory changes that can lead to progressive liver damage, cirrhosis, and hepatocellular carcinoma. Recent studies have shown that in addition to genetic predisposition and diet, the gut microbiota affects hepatic carbohydrate and lipid metabolism as well as influences the balance between pro‐inflammatory and anti‐inflammatory effectors in the liver, thereby impacting NAFLD and its progression to NASH. In this review, we will explore the impact of gut microbiota and microbiota‐derived compounds on the development and progression of NAFLD and NASH, and the unexplored factors related to potential microbiome contributions to this common liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activation of these TLRs can contribute to the development of NAFLD and nonalcoholic steatohepatitis (NASH), with the most extensively studied pathway being LPS-TLR4 signaling.180”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245 · cited 2×
“However, conven-tionalization of germ-free mice with normal mouse microbiota induces de novo hepatic lipogenesis, in addition to increased body fat content and insulin resistance (Ba¨ckhed et al , 2004).”
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Intestinal mucosal barrier function in health and disease
Turner, J. R. (2009) · Nature reviews. Immunology · doi:10.1038/nri2653 · Cited by 3,952 · cited 1×
“Under physiological conditions, tight junction proteins, such as zonula occludens, seal adjacent epithelial cells at the apical sites and prevent bacteria from entering the intestinal mucosa and the bloodstream (Turner, 2009).”
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 1×
“…in the digestion of food and facilitates the absorption of the dietary molecules into the portal and systemic circulation (Jumpertz et al , 2011; Ridaura et al , 2013), interacts with the mucosal immune system, to shape development of its antigen recognition, recruitment, proliferation, and…”
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., Schilter, H. C., Rolph, M. S., Mackay, F., Artis, D., et al. (2009) · Nature · doi:10.1038/nature08530 · Cited by 3,241 · cited 3×
“In addition, SCFAs are also potent signaling molecules through binding to G-protein-coupled receptors GPR41, GPR43, and GPR109A (Samuel et al , 2008; Maslowski et al , 2009).”
Research works printed but not linked: 1
- Ackermann D, Schutze H (1910) The formation of trimethylamine by bacterium prodigiosum. Zentralb Physiol 24: 210–211
Cited by
Interaction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947
Self-citationFrom NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
The intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089
Self-citationGut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,063
Phage therapy: From biological mechanisms to future directions
Strathdee, S. A., Hatfull, G. F., Mutalik, V. K., & Schooley, R. T. (2023) · Cell · doi:10.1016/j.cell.2022.11.017 · Cited by 817
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Macrophage Polarization and Its Role in Liver Disease
Wang, C., Ma, C., Gong, L., Guo, Y., Fu, K., Zhang, Y., Zhou, H., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803037 · Cited by 581
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430
“, enhanced liver fibrosis,[83] N- terminal type III collagen propeptide [ProC3]/ProC5), proteomics,[84] lipidomics,[85] microRNAs,[86,87] and components of the microbiome[88]; (2) imaging tests (CT, MRI, or positron emission tomography) that can quantify liver fat, inflammation, fibrosis, as well as liver stiffness as…”
BackgroundPain regulation by gut microbiota: molecular mechanisms and therapeutic potential
Guo, R., Chen, L.-H., Xing, C., & Liu, T. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.07.026 · Cited by 405
Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
Chen, J., & Vitetta, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155214 · Cited by 352
Multidimensional Impact of Mediterranean Diet on IBD Patients
Chicco, F., Magrì, S., Cingolani, A., Paduano, D., Pesenti, M., Zara, F., Tumbarello, F., Urru, E., Melis, A., Casula, L., et al. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa097 · Cited by 290
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial
Yaskolka Meir, A., Rinott, E., Tsaban, G., Zelicha, H., Kaplan, A., Rosen, P., Shelef, I., Youngster, I., Shalev, A., Blüher, M., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323106 · Cited by 287
Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
Aron-Wisnewsky, J., Warmbrunn, M. V., Nieuwdorp, M., & Clément, K. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.049 · Cited by 239
Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease
Cong, J., Zhou, P., & Zhang, R. (2022) · Nutrients · doi:10.3390/nu14091977 · Cited by 231
Non‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management
Huang, T. (., Behary, J., & Zekry, A. (2020) · Internal Medicine Journal · doi:10.1111/imj.14709 · Cited by 227
New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries
Jain, T., Sharma, P., Are, A. C., Vickers, S. M., & Dudeja, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622064 · Cited by 183
Muriel, P., López-Sánchez, P., & Ramos-Tovar, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136969 · Cited by 156
Diet, nutrients and the microbiome
(2020) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2020.04.006 · Cited by 170
Okamura, T., Hamaguchi, M., Hasegawa, Y., Hashimoto, Y., Majima, S., Senmaru, T., Ushigome, E., Nakanishi, N., Asano, M., Yamazaki, M., et al. (2023) · Environmental Health Perspectives · doi:10.1289/ehp11072 · Cited by 179
Fei, N., Bruneau, A., Zhang, X., Wang, R., Wang, J., Rabot, S., Gérard, P., & Zhao, L. (2020) · mBio · doi:10.1128/mbio.03263-19 · Cited by 168
Yi, H., Peng, H., Wu, X., Xu, X., Kuang, T., Zhang, J., Du, L., & Fan, G. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6678662 · Cited by 165
Internalization of Garlic-Derived Nanovesicles on Liver Cells is Triggered by Interaction With CD98
Song, H., Canup, B. S. B., Ngo, V. L., Denning, T. L., Garg, P., & Laroui, H. (2020) · ACS Omega · doi:10.1021/acsomega.0c02893 · Cited by 149
Ma, L., Li, H., Hu, J., Zheng, J., Zhou, J., Botchlett, R., Matthews, D., Zeng, T., Chen, L., Xiao, X., et al. (2020) · Hepatology · doi:10.1002/hep.31115 · Cited by 147
Meroni, M., Longo, M., & Dongiovanni, P. (2019) · Nutrients · doi:10.3390/nu11112642 · Cited by 140
Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 157
Carpi, R. Z., Barbalho, S. M., Sloan, K. P., Laurindo, L. F., Gonzaga, H. F., Grippa, P. C., Zutin, T. L. M., Gírio, R. J. S., Repetti, C. S. F., Detregiachi, C. R. P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158805 · Cited by 154
Metabolic Targets in Nonalcoholic Fatty Liver Disease
Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 144
Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
Zarghamravanbakhsh, P., Frenkel, M., & Poretsky, L. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100149 · Cited by 131
Harrison, S. A., Gunn, N., Neff, G. W., Kohli, A., Liu, L., Flyer, A., Goldkind, L., & Bisceglie, A. M. D. (2021) · Nature Communications · doi:10.1038/s41467-021-25701-5 · Cited by 140
Hepatic sexual dimorphism — implications for non-alcoholic fatty liver disease
Lefèbvre, P., & Staels, B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00538-6 · Cited by 143
Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut–liver axis
Han, H. L., Jiang, Y., Wang, M., Melaku, M., Liu, L., Zhao, Y. M., Everaert, N., Yi, B., & Zhang, H. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1966738 · Cited by 141
Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges
Goldner, D. L., & Lavine, J. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.048 · Cited by 149
Yang, M. J., Qi, X., Li, N., Kaifi, J. T., Chen, S., Wheeler, A. A., Kimchi, E. T., Ericsson, A. C., Rector, R. S., Staveley-O’Carroll, K. F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35861-1 · Cited by 141
Khan, A., Ding, Z., Ishaq, M. H., Bacha, A. S., KHAN, I. A., Hanif, A., Li, W., & Guo, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.56214 · Cited by 140
Drescher, H., Weiskirchen, S., & Weiskirchen, R. (2019) · Cells · doi:10.3390/cells8080845 · Cited by 134
A successful history: probiotics and their potential as antimicrobials
Santacroce, L., Charitos, I. A., & Bottalico, L. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1645597 · Cited by 142
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
Boeckmans, J., Natale, A., Rombaut, M., Buyl, K., Rogiers, V., De Kock, J., Vanhaecke, T., & Rodrigues, R. M. (2019) · Cells · doi:10.3390/cells9010037 · Cited by 122
Zhang, Z., Ran, C., Ding, Q., Liu, H.-L., Xie, M., Yang, Y., Xie, Y.-D., Gao, C., Zhang, H., & Zhou, Z. (2019) · Communications Biology · doi:10.1038/s42003-019-0526-z · Cited by 126
Soto-Angona, Ó., Anmella, G., Valdés-Florido, M. J., De Uribe-Viloria, N., Carvalho, A. F., Penninx, B. W. J. H., & Berk, M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01713-8 · Cited by 122
Gut microbiota and immunity relevance in eubiosis and dysbiosis
Al-Rashidi, H. E. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.10.068 · Cited by 105
Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact
Caturano, A., Acierno, C., Nevola, R., Pafundi, P. C., Galiero, R., Rinaldi, L., Salvatore, T., Adinolfi, L. E., & Sasso, F. C. (2021) · Processes · doi:10.3390/pr9010135 · Cited by 104
Kotsiliti, E., Leone, V., Schuehle, S., Govaere, O., Li, H., Wolf, M. J., Horvatic, H., Bierwirth, S., Hundertmark, J., Inverso, D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.037 · Cited by 108
Self-citationChen, X., Zhang, Z., Li, H., Zhao, J., Wei, X., Lin, W., Zhao, X., Jiang, A., & Yuan, J. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15027 · Cited by 95
Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease
Katsarou, A., Moustakas, I. I., Pyrina, I., Lembessis, P., Koutsilieris, M., & Chatzigeorgiou, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i17.1993 · Cited by 115
Microbial Metabolites: Critical Regulators in NAFLD
Dai, X., Hou, H., Zhang, W., Liu, T., Li, Y., Wang, S., Wang, B., & Cao, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.567654 · Cited by 111
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
Lee, Y. A., & Friedman, S. L. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13380 · Cited by 108
Lei, Y., Tang, L., Chen, Q., Wu, L., He, W., Tu, D., Wang, S., Chen, Y., Liu, S., Xie, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34671-1 · Cited by 104
NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
Pinter, M., Pinato, D. J., Ramadori, P., & Heikenwalder, M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1258 · Cited by 103
“In this setting, an important contribution is also given by the adipose tissue and the gut microbiota, which fuel the inflammatory milieu in response to changes of tissue homeostasis (25, 26).”
BackgroundAntibiotic pretreatment alleviates liver transplant damage in mice and humans
Nakamura, K., Kageyama, S., Ito, T., Hirao, H., Kadono, K., Aziz, A., Dery, K. J., Everly, M. J., Taura, K., Üemoto, S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127550 · Cited by 102
Chen, Z., Zhang, Z., Liu, J., Qi, H., Li, J., Chen, J., Huang, Q., Liu, Q., Mi, J., & Li, X. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.853981 · Cited by 111
Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury
Rodriguez, C., Taminiau, B., García-García, A., Cueto‐Sánchez, A., Robles‐Díaz, M., Ortega‐Alonso, A., Martín‐Reyes, F., Daube, G., Sanabria‐Cabrera, J., Pérez, M. J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106348 · Cited by 101
Thibaut, R., Gage, M. C., Pineda‐Torra, I., Chabrier, G., Venteclef, N., & Alzaid, F. (2022) · The FEBS Journal · doi:10.1111/febs.15877 · Cited by 95
Kuchay, M. S., Martínez‐Montoro, J. I., Kaur, P., Fernández‐García, J. C., & Ramos‐Molina, B. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101696 · Cited by 93
Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases
Hyun, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179139 · Cited by 90
Bocanegra, A., Macho‐González, A., Garcimartín, A., Benedí, J., & Sánchez-Muniz, F. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083816 · Cited by 97
Li, Y., Zhao, D., Qian, M., Liu, J., Pan, C., Zhang, X., Duan, X., Zhang, Y., Jia, W., & Wang, L. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15768 · Cited by 88
Basil, B., Myke-Mbata, B. K., Eze, O. E., & Akubue, A. U. (2024) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-024-00187-4 · Cited by 86
Wang, L., Ai, C., Wen, C., Qin, Y., Liu, Z., Wang, L., Gong, Y., Su, C., Wang, Z., & Song, S. (2020) · Food & Function · doi:10.1039/d0fo00668h · Cited by 85
Risk factors in nonalcoholic fatty liver disease
Ko, E., Yoon, E. L., & Jun, D. W. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0398 · Cited by 89
Su, X. B., Chen, S., Liu, J., Feng, Y., Han, E., Hao, X., Liao, M., Cai, J., Zhang, S., Niu, J., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13646 · Cited by 89
Saeed, H., Díaz, L. A., Gil‐Gómez, A., Burton, J. P., Bajaj, J. S., Romero‐Gómez, M., Arrese, M. A., Arab, J. P., & Khan, M. Q. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0811 · Cited by 91
He, Z., Li, X., Yang, H., Wu, P., Wang, S., Cao, D., Guo, X. C., Xu, Z., Gao, J., Zhang, W., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.745609 · Cited by 90
Chronic lead exposure induces fatty liver disease associated with the variations of gut microbiota
Wan, H., Wang, Y., Zhang, H., Zhang, K., Chen, Y., Chen, C., Zhang, W., Xia, F., Wang, N., & Lu, Y. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113257 · Cited by 83
Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD
Jiang, X., Zheng, J., Zhang, S., Wang, B., Wu, C., & Guo, X. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00361 · Cited by 90
Lean NAFLD: an underrecognized and challenging disorder in medicine
Maier, S., Wieland, A. C., Cree‐Green, M., Nadeau, K. J., Sullivan, S. A., Lanaspa, M. A., Johnson, R. J., & Jensen, T. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09621-1 · Cited by 85
Peiseler, M., & Tacke, F. (2021) · Cancers · doi:10.3390/cancers13040730 · Cited by 71
Liu, S., Gao, Z., He, W., Wu, Y., Liu, J., Zhang, S., Yan, L., Mao, S., Shi, X., Fan, W., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.10.270 · Cited by 82
The Role of the Human Microbiome in the Pathogenesis of Pain
Ustianowska, K., Ustianowski, Ł., Machaj, F., Gorący, A., Rosik, J., Szostak, B., Szostak, J., & Pawlik, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113267 · Cited by 85
Xie, Y., Zou, X., Han, J., Zhang, Z., Feng, Z., Ouyang, Q., Hua, S., Liu, Z., Li, C., Cai, Y., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114081 · Cited by 80
Plasticity of Intestinal Epithelium: Stem Cell Niches and Regulatory Signals
Kurokawa, K., Hayakawa, Y., & Koike, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010357 · Cited by 82
Establishment of the early-life microbiome: a DOHaD perspective
Stinson, L. F. (2019) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174419000588 · Cited by 82
Fianchi, F., Liguori, A., Gasbarrini, A., Grieco, A., & Miele, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126485 · Cited by 82
Yang, K., & Song, M. J. (2023) · Nutrients · doi:10.3390/nu15183970 · Cited by 88
Lipid Disorders and Metabolic-Associated Fatty Liver Disease
Anwar, S. D., Foster, C., & Ashraf, A. P. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.01.003 · Cited by 78
Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer
Kaffe, E., Magkrioti, C., & Aidinis, V. (2019) · Cancers · doi:10.3390/cancers11111626 · Cited by 73
Li, D., Cui, Y., Wang, X., Liu, F., & Li, X. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c02532 · Cited by 75
Bellais, S., Nehlich, M., Ania, M., Duquenoy, A., Mazier, W., van den Engh, G., Baijer, J., Treichel, N. S., Clavel, T., Belotserkovsky, I., et al. (2022) · Microbiome · doi:10.1186/s40168-021-01206-7 · Cited by 77
Lu, T., Li, Q., Lin, W., Zhao, X., Fu, L., Ji, J., Zhang, Y., & Xu, N. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.01.004 · Cited by 73
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis
Silveira, M. A. D., Bilodeau, S., Greten, T. F., Wang, X. W., & Trinchieri, G. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.02.009 · Cited by 73
Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?
Jiang, L., & Schnabl, B. (2020) · Physiology · doi:10.1152/physiol.00005.2020 · Cited by 77
Microbiota, Fiber, and NAFLD: Is There Any Connection?
de, A. P.-M., Julián, M. T., Ramos, A., Puig‐Domingo, M., & Alonso, N. (2020) · Nutrients · doi:10.3390/nu12103100 · Cited by 74
Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
Carreres, L., Jílková, Z. M., Vial, G., Marche, P. N., Decaens, T., & Lerat, H. (2021) · Biomedicines · doi:10.3390/biomedicines9040378 · Cited by 74
Spremović-Radjenović, S., Pupovac, M., Andjić, M., Bila, J. S., Sreckovic, S. D., Gudović, A., Dragaš, B., & Radunović, N. V. (2022) · Biomedicines · doi:10.3390/biomedicines10010131 · Cited by 78
Takahashi, S., Luo, Y., Ranjit, S., Xie, C., Libby, A. E., Orlicky, D. J., Dvornikov, A. S., Wang, X. X., Myakala, K., Jones, B. A., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011913 · Cited by 67
Liang, W., Zhou, K., Jian, P., Chang, Z., Zhang, Q., Liu, Y., Xiao, S., & Zhang, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.622841 · Cited by 68
Trabelsi, K., Ammar, A., Boujelbane, M. A., Puce, L., Garbarino, S., Scoditti, E., Boukhris, O. F., Khanfir, S., Clark, C. C. T., Glenn, J. M., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1036496 · Cited by 74
Jayachandran, M., & Qu, S. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09843-z · Cited by 66
Dietary protein insufficiency: an important consideration in fatty liver disease?
Ampong, I., Watkins, A. J., Gutierrez‐Merino, J., Ikwuobe, J., & Griffiths, H. R. (2019) · British Journal Of Nutrition · doi:10.1017/s0007114519003064 · Cited by 66
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.006 · Cited by 63
Hu, W., Gong, W., Yang, F., Cheng, R., Zhang, G., Gan, L., Zhu, Y., Qin, W., Gao, Y., Li, X., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113937 · Cited by 66
Zhou, Y., Wang, M., Wang, Z., Qiu, J., Wang, Y., Li, J., Dong, F., Huang, X., Zhao, J., & Xu, T. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156458 · Cited by 64
Lin, W., Yue, F., Lin, X., Wu, S., Shi, Y., Li, J., Xiang, X., Lam, S. M., Shui, G., Russell, R., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01975 · Cited by 64
Inflammatory signaling in NASH driven by hepatocyte mitochondrial dysfunctions
Myint, M., Oppedisano, F., De Giorgi, V., Kim, B.-M., Marincola, F. M., Alter, H. J., & Nesci, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04627-0 · Cited by 61
Dua, A., KUMARI, R. R., Singh, M., Kumar, R., Pradeep, S., Ojesina, A. I., & Kumar, R. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1618275 · Cited by 72
Li, X., Zhao, W., Meng, X., Yu, L., Chen, Q., Hu, X., Zhao, Y., Xiong, L., Chen, X., Wang, X., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115333 · Cited by 61
Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis
Rui, L., & Lin, J. D. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062220-105200 · Cited by 56
Zhang, R., Yan, Z., Zhong, H., Rong, L., Liu, W., Xiong, S., Liu, Q., & Liu, M. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000484 · Cited by 60
Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies
Leylabadlo, H. E., Ghotaslou, R., Kafil, H. S., Feizabadi, M. M., Moaddab, S. Y., Farajnia, S., Sheykhsaran, E., Sanaie, S., Shanehbandi, D., & Baghi, H. B. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03746-1 · Cited by 60
Yao, Z., Zhao, M., Gong, Y., Chen, W., Wang, Q., Fu, Y., Guo, T., Zhao, J., Gao, L., & Bo, T. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00495 · Cited by 62
Hashemian, M., Merat, S., Poustchi, H., Jafari, E., Radmard, A.-R., Kamangar, F., Freedman, N. D., Hekmatdoost, A., Sheikh, M., Boffetta, P., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001229 · Cited by 60
Metadata
- Authors
- Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E.
- Affiliations
- Weizmann Institute of Science (IL)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Tel Aviv Sourasky Medical Center (IL)
- Corresponding author
- Elinav, Eran
- Venue
- EMBO Molecular Medicine
- Published
- 2018-12-27
- Volume
- 11
- Issue
- 2
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC6365925
- OpenAlex
- W2907493655
- Cited by
- 523
- References
- 125
- Citations by year
- 2026: 30 · 2025: 63 · 2024: 73 · 2023: 94 · 2022: 91 · 2021: 76 · 2020: 71 · 2019: 25
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- European Union's Horizon 2020 (747114)
- European Crohn's and Colitis Organization (ECCO) Fellowship
- Ke Lin Program of the First Affiliated Hospital of Sun Yat‐sen University
- Alexander Grass foundation
- Y. and R. Ungar
- Gurwin Family Fund for Scientific Research
- Crown Endowment Fund for Immunological Research
- Else Kroener‐Fresenius Foundation
- Benoziyo Endowment Fund for the Advancement of Science
- Adelis Foundation
- French National Center for Scientific Research
- European Research Council
- Marie Curie Integration grant
- Rising Tide Foundation
- Helmholtz Foundation
- Canadian Institute of Advanced Research
- The Bill & Melinda Gates Foundation & Howard Hughes Medical Institute
- Abisch‐Frenkel Foundation for the Promotion of Life Sciences
- Leona M. and Harry B. Helmsley Charitable Trust
- German–Israeli Foundation for Scientific Research and Development
- Israel Science Foundation
- Minerva Foundation
- European Foundation for the Study of Diabetes
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, gut microbiota, microbiome, cardiometabolic syndrome, obesity, diabetes mellitus, dyslipidemia, hepatic lipid metabolism, hepatic carbohydrate metabolism, inflammation, gut microbiota metabolites, liver cirrhosis, hepatocellular carcinoma
- MeSH terms
- Gastrointestinal Microbiome, Bacteria, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Disease Progression, Carbohydrate Metabolism, Lipid Metabolism, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.